Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Adopts FY2021 Project Plans with Focus on Pricing Reform
March 19, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- 76% Sees Healthcare as Top Priority in COVID-19 Response: PhRMA Japan Survey
February 19, 2021
- PhRMA Japan Chief Urges Govt to Return to Pro-Innovation Path, Airs Grievances over Decision-Making on Off-Year Price Cuts
February 19, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
- PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
- JPMA, National Centers to Build Integrated Database for Drug Discovery; 1st Focus on Neurology/Psychiatry, Immune/Inflammation
January 26, 2021
- 3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
- JPMA Exec Raps Off-Year Re-Pricing Plan, Says It Significantly Mars Predictability
January 22, 2021
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
- First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
January 5, 2021
- Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
January 5, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…